Anixa Biosciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $150.59 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Anixa Biosciences Inc had its IPO on 1987-01-01 under the ticker symbol ANIX.
The company operates in the Healthcare sector and Biotechnology industry. Anixa Biosciences Inc has a staff strength of 4 employees.
Shares of Anixa Biosciences Inc opened at $4.26 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $4.18 - $4.38, and closed at $4.36.
This is a +1.16% increase from the previous day's closing price.
A total volume of 38,336 shares were traded at the close of the day’s session.
In the last one week, shares of Anixa Biosciences Inc have slipped by -2.68%.
Anixa Biosciences Inc's Key Ratios
Anixa Biosciences Inc has a market cap of $150.59 million, indicating a price to book ratio of 4.3718 and a price to sales ratio of 156.9819.
In the last 12-months Anixa Biosciences Inc’s revenue was $-500 with a gross profit of $127498 and an EBITDA of $-13097416. The EBITDA ratio measures Anixa Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Anixa Biosciences Inc’s operating margin was 0% while its return on assets stood at -26.02% with a return of equity of -43.74%.
In Q3.3333333333333, Anixa Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Anixa Biosciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Anixa Biosciences Inc’s profitability.
Anixa Biosciences Inc stock is trading at a EV to sales ratio of 91.0091 and a EV to EBITDA ratio of -7.4957. Its price to sales ratio in the trailing 12-months stood at 156.9819.
Anixa Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $30.41 million
- Total Liabilities
- $2.04 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Anixa Biosciences Inc ended 2023 with $30.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.41 million while shareholder equity stood at $29.05 million.
Anixa Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $2.04 million in other current liabilities, 309000.00 in common stock, $-218385000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.36 million and cash and short-term investments were $29.69 million. The company’s total short-term debt was $46,000 while long-term debt stood at $0.
Anixa Biosciences Inc’s total current assets stands at $30.20 million while long-term investments were $0 and short-term investments were $17.33 million. Its net receivables were $0 compared to accounts payable of $265000.00 and inventory worth $0.
In 2023, Anixa Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Anixa Biosciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Anixa Biosciences Inc stock is currently trading at $4.36 per share. It touched a 52-week high of $6.25 and a 52-week low of $6.25. Analysts tracking the stock have a 12-month average target price of $9.5.
Its 50-day moving average was $4.39 and 200-day moving average was $4.31 The short ratio stood at 14.09 indicating a short percent outstanding of 0%.
Around 453.4% of the company’s stock are held by insiders while 1182.4% are held by institutions.
Frequently Asked Questions About Anixa Biosciences Inc
Similar Industry Stocks (Biotechnology)
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.